Cristiane Bergerot, Director of the Department of Psycho-Oncology at CETTRO Cancer Research Hospital, shared a post on X:
“Fascinating data from ASCO25!
Sumanta K. Pal presented genomic insights from IMmotion010 — KIM-1 remains the most robust predictor of atezo benefit, with NMF6 (stromal/proliferative) tumors also showing promising DFS. Important steps toward personalized adjuvant therapy in RCC.”
Bergerot commented on data presented by Sumanta K. Pal at ASCO25 from the IMmotion010 trial, highlighting KIM-1 and NMF6 as key biomarkers for guiding adjuvant atezolizumab therapy in renal cell carcinoma.
More posts featuring Cristiane Bergerot.
